Effect of triflusal and acetylsalicylic acid on platelet aggregation in human whole blood: influence of red blood cells and leukocytes.
A study has been made on the in vitro effect of triflusal, acetylsalicylic acid (ASA and their major metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid (HTB), and salicylic acid (SA), on platelet aggregation in human whole blood. SA exhibited no significant antiplatelet effects (IC50 greater than 2mM) against several inducers; the IC50 values for the other compounds were: triflusal, 140 microM against ADP and 63.2 microM against collagen; HTB, 100 microM against ADP and 260 microM against collagen; ASA 687 microM against ADP and 9.3 microM against collagen. Red blood cells potentiate the antiaggregant effect of HTB and of triflusal, and to a lesser extent, that of ASA; leukocytes primarily potentiate the effect of ASA and, to a lesser extent, that of triflusal.
de la Cruz
J P
JP
Department of Pharmacology and Therapeutics, School of Medicine, University of Malaga, Spain.
Pavia
J
J
Bellido
I
I
Sánchez de la Cuesta
F
F
D000328:Adult; D001241:Aspirin / Q000494:pharmacology*; D004912:Erythrocytes / Q000502:physiology*; D006801:Humans; D066298:In Vitro Techniques; D007962:Leukocytes / Q000502:physiology*; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D012459:Salicylates / Q000494:pharmacology*; D020156:Salicylic Acid
D010975:Platelet Aggregation Inhibitors; D012459:Salicylates; C016167:triflusal; D020156:Salicylic Acid; D001241:Aspirin